Document is current
Any future updates will be listed below
-
Authors
Alonso-Beato, Rubén
Demelo-Rodríguez, Pablo https://orcid.org/0000-0002-3096-4711
Ordieres-Ortega, Lucía
López-Rubio, Marina
Lago-Rodríguez, Marta-Olimpia
Oblitas, Crhistian-Mario
Alvarez-Sala Walther, Luis Antonio
Galeano-Valle, Francisco
-
Funding
Funding for this research was provided by:
Universidad Complutense de Madrid
- License Information
-
More Information
Article History
Received: 26 May 2025
Accepted: 24 June 2025
First Online: 3 July 2025
Declarations
:
: Dr. Demelo-Rodríguez has received speaker’s honoraria from the following pharmaceutical companies: ROVI, Bayer, Techdow, Menarini, Leo Pharma, Pfizer, Bristol-Myers, Sanofi, and Daiichi-Sankyo. In addition, he has engaged in advisory consultancy work for Techdow, Leo Pharma, and Pfizer. Dr. Ordieres-Ortega has received speaker’s honoraria from Daiichi-Sankyo. Additionally, she has engaged in advisory consultancy work for Takeda. Dr. Oblitas has received speaker’s honoraria from the following pharmaceutical companies: ROVI and Leo Pharma. Dr. Alvarez-Sala Walther has received speaker’s honoraria from the following pharmaceutical companies: Daiichi-Sankyo, Amgen, Sanofi and Amarin. Dr. Galeano-Valle has received speaker’s honoraria from the following pharmaceutical companies: Leo Pharma, ROVI, Techdow, Pfizer, Bristol-Myers, and Daiichi-SankyoThe rest of the authors have no conflicts of interest to declare.
